Validation of the REMA Score for Predicting Mast Cell Clonality and Systemic Mastocytosis in Patients with Systemic Mast Cell Activation Symptoms
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: A variable percentage of patients with systemic mast cell (MC) activation symptoms meet criteria for systemic mastocytosis (SM). We prospectively evaluated the clinical utility of the REMA score versus serum baseline tryptase (sBt) levels for predicting MC clonality and SM in 158 patients with systemic MC activation symptoms in the absence of mastocytosis in the skin (MIS). Methods: World Health Organization criteria for SM were applied in all cases. MC clonality was defined as the presence of KIT-mutated MC or by a clonal HUMARA test. The REMA score consisted of the assignment of positive or negative points as follows: male (+1), female (–1), sBt <15 µg/l (–1) or >25 µg/l (+2), presence (–2) or absence (+1) of pruritus, hives or angioedema and presence (+3) of presyncope or syncope. Efficiency of the REMA score for predicting MC clonality and SM was assessed by receiver operating characteristic (ROC) curve analyses and compared to those obtained by means of sBt levels alone. Results: Molecular studies revealed the presence of clonal MC in 68/80 SM cases and in 11/78 patients who did not meet the criteria for SM. ROC curve analyses confirmed the greater sensitivity and a similar specificity of the REMA score versus sBt levels (84 vs. 59% and 74 vs. 70% for MC clonality and 87 vs. 62% and 73 vs. 71% for SM, respectively). Conclusions: Our results confirm the clinical utility of the REMA score to predict MC clonality and SM in patients suffering from systemic MC activation symptoms without MIS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indirect signs for the presence of an underlying (occult) SM include an elevated baseline serum tryptase level detected well after complete resolution of all symptoms or a D816V KIT mutation in circulating blood leukocytes, blood count abnormalities (e.g., eosinophilia), symptoms suggestive of SM such as unexplained osteoporosis, gastrointestinal symptoms (diarrhea, abdominal cramps, malabsorption”
From Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome (2019) · cites this paper as [60]
In the citing paper
“The most commonly used and validated is the REMA-score (Red Española de Mastocitosis (Spanish Network on Mastocytosis)) [57], which was initially developed for Hymenoptera venom allergy and later extended to other causes of anaphylaxis.”
From Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders (2023) · cites this paper as [57]
In the citing paper
“The Spanish Network on Mastocytosis score (REMAs) is a validated tool based on combined clinical and laboratory criteria to predict underlying MC clonality risk in patients presenting with anaphylaxis without typical mastocytosis skin changes.12,13”
From Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders (2024) · cites this paper as [12]
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Bock, S. A., Branum, A., Brown, S. G. A., Camargo, C. A., Cydulka, R., Galli, S. J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1303 · Cited by 2,313
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750
Self-citationGarcia-Montero, A. C. (2006) · Blood · doi:10.1182/blood-2006-04-015545 · Cited by 504
Self-citationMast cell activation syndrome: Proposed diagnostic criteria
Akin, C., Valent, P., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.035 · Cited by 327
Álvarez-Twose, I., González de Olano, D., Sánchez-Muñoz, L., Matito, A., Esteban-López, M. I., Vega, A., Mateo, M. B., Alonso Díaz de Durana, M. D., de la Hoz, B., del Pozo Gil, M. D., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.019 · Cited by 294
Self-citationEscribano, L., Álvarez-Twose, I., Sánchez-Muñoz, L., Garcia-Montero, A., Núñez, R., Almeida, J., Jara-Acevedo, M., Teodósio, C., García-Cosío, M., Bellas, C., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.003 · Cited by 292
Self-citationEscribano, L., Diaz‐Agustin, B., López, A., Núñez López, R., García‐Montero, A., Almeida, J., Prados, A., Angulo, M., Herrero, S., Orfao, A., et al. (2004) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.10072 · Cited by 147
Self-citationWu, Y., Basir, Z., Kajdacsy-Balla, A., Strawn, E., Macias, V., Montgomery, K., & Guo, S.-W. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04821-5 · Cited by 114
Evaluation of the WHO criteria for the classification of patients with mastocytosis
Sánchez‐Muñoz, L., Álvarez‐Twöse, I., García‐Montero, A. C., Teodósio, C., Jara‐Acevedo, M., Pedreira, C. E., Matito, A., Morgado, J. M., Sánchez, M. L., Mollejo, M., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.84 · Cited by 105
Self-citationSperr, W. R., El‐Samahi, A., Kundi, M., Girschikofsky, M., Winkler, S., Lutz, D., Endler, G., Rumpold, H., Agis, H., Sillaber, C., et al. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02184.x · Cited by 98
Serum total tryptase levels are increased in patients with active chronic urticaria
Ferrer, M., Nuñez‐Córdoba, J. M., Luquin, E., Grattan, C. E., De la Borbolla, J. M., Sanz, M. L., & Schwartz, L. B. (2010) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2010.03582.x · Cited by 72
Assessing anaphylactic risk? Consider mast cell clonality
Metcalfe, D. D., & Schwartz, L. B. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.02.003 · Cited by 52
Sánchez‐Muñoz, L., Teodósio, C., Morgado, J. M., & Escribano, L. (2011) · Methods in cell biology · doi:10.1016/b978-0-12-385493-3.00014-0 · Cited by 48
Self-citation
Cited by
Anaphylaxis: A 2023 practice parameter update
Golden, D. B. K., Wang, J., Waserman, S., Akin, C., Campbell, R. L., Ellis, A. K., Greenhawt, M., Lang, D. M., Ledford, D. K., Lieberman, J., et al. (2024) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2023.09.015 · Cited by 347
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Brockow, K., Niedoszytko, M., Nedoszytko, B., Siebenhaar, F., Sperr, W. R., Oude Elberink, J. N. G., et al. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.01.006 · Cited by 225
“Indirect signs for the presence of an underlying (occult) SM include an elevated baseline serum tryptase level detected after complete resolution of all symptoms or a D816V KIT mutation in circulating blood leukocytes, blood cell count abnormalities (eg, eosinophilia), symptoms suggestive of SM such as unexplained ost…”
BackgroundValent, P., Escribano, L., Broesby‐Olsen, S., Hartmann, K., Grattan, C., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, J. N. G., Kristensen, T., et al. (2014) · Allergy · doi:10.1111/all.12436 · Cited by 174
Self-citationHuman mast cell tryptase in biology and medicine
Vitte, J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2014.04.001 · Cited by 152
Álvarez-Twose, I., Zanotti, R., González-de-Olano, D., Bonadonna, P., Vega, A., Matito, A., Sánchez-Muñoz, L., Morgado, J. M., Perbellini, O., García-Montero, A., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.020 · Cited by 142
Self-citation
Metadata
- Authors
- Alvarez-Twose, I., González-de-Olano, D., Sánchez-Muñoz, L., Matito, A., Jara-Acevedo, M., Teodosio, C., García-Montero, A., Morgado, J. M., Orfao, A., & Escribano, L.
- Affiliations
- Hospital Virgen del Valle (ES)
- Universidad de Salamanca (ES)
- Venue
- International Archives of Allergy and Immunology
- Publisher
- S. Karger AG
- Published
- 2011-10-28
- Volume
- 157
- Issue
- 3
- Pages
- 275-280
- ISSN
- 1018-2438 (ISSN-L)
- 1423-0097
- OpenAlex
- W2033518553
- Cited by
- 184
- References
- 15
- Citations by year
- 2026: 3 · 2025: 19 · 2024: 16 · 2023: 13 · 2022: 18 · 2021: 15 · 2020: 14 · 2019: 16 · 2018: 11 · 2017: 23 · 2016: 6 · 2015: 9 · 2014: 11 · 2013: 4 · 2012: 5
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- International Archives of Allergy and Immunology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- systemic mastocytosis, serum tryptase, KIT mutations, pruritus, angioedema, diagnostic prediction
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Decision Support Techniques, Female, Humans, Male, Mast Cells, Middle Aged, Prospective Studies, Pruritus, ROC Curve, Sex Factors, Syncope, Urticaria, Biomarkers, Proto-Oncogene Proteins c-kit, Mastocytosis, Systemic, Tryptases, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.